The study found that fewer than 1% of eligible older adults were prescribed an anti-obesity GLP-1 RA medication (0.2% of Medicare-aged patients and 0.4% of patients aged 60-64)
What about retatrutide and survodutide: do the newer drugs hit muscle harder
Samoilov, M., Plyasunov, S
The right day depends on your personal schedule and when you can most comfortably manage digestive side effects
GLP-1 use notwithstanding, determining the cause of a performance decline can be challenging
But retatrutide may be even more effective , for several reasons: Glucagon receptor activation promotes hepatic fat oxidation Reduces liver fat accumulation more robustly Improves liver enzyme levels (ALT, AST) In a subgroup analysis of the retatrutide Phase 2 trial: Patients with suspected NAFLD showed a 70%+ reduction in liver fat content , measured by MRI-PDFF These effects surpassed the reductions seen with tirzepatide and semaglutide in comparable studies Another study showed that 93% of patients on the highest dose of retatrutide had 100% resolution of fatty liver